• Explore /
  • Poster
  • / Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.

Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.

Abstract Poster

Authors

null

Panpan Zhang

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China

Panpan Zhang , Ming Lu , Lin Shen , Lijie Song , Yanqiao Zhang , Zhendong Chen , Ying Cheng , Zhiping Li , Xing Zhang , Jinghong Zhou , Haiyan Shi , Panfeng Tan , Songhua Fan , Dingpan Liu , Michael Shi , Weiguo Su

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Immunotherapies

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 36)

DOI

10.1200/JCO.2024.42.23_suppl.36

Abstract #

36

Poster Bd #

A9

Abstract Disclosures

Similar Posters

First Author: Ying Cheng

First Author: Qing Zhou

First Author: Tony S. K. Mok

First Author: TAO Haitao